Patient demographics
| Category . | AML . | MDS . | |
|---|---|---|---|
| New . | Relapsed . | ||
| No. of cases | 125 | 37 | 100 |
| Sex, female/male | 65/60 | 14/23 | 26/74 |
| Median age (range), y | 62.18 (21-86) | 55.48 (19-73) | 64.45 (21-83) |
| Race | |||
| American Indian | 0 | 1 | 0 |
| Asian | 1 | 1 | 2 |
| Black | 5 | 0 | 2 |
| Hispanic | 9 | 5 | 6 |
| White | 110 | 30 | 90 |
| FAB | |||
| Unknown | 2 | 8 | 2 (unknown) |
| M0 | 7 | 1 | 11 (CMML) |
| M1 | 12 | 6 | 17 (RA) |
| M2 | 50 | 10 | 10 (RARS) |
| M4 | 25 | 9 | 44 (RAEB) |
| M4Eos | 6 | 0 | 16 (RAEBT) |
| M5 | 12 | 2 | |
| M6 | 5 | 1 | |
| M7 | 4 | 0 | |
| Status | |||
| New | 125 | 0 | 83 |
| Post biologic | 0 | 0 | 12 |
| Relapsed | 0 | 36 | 2 |
| Relapsed resistant | 0 | 1 | 3 |
| Cytogenetics | |||
| t(8:21) | 1 | 1 | 0 |
| Inversion16 | 6 | 0 | 1 |
| Diploid | 55 | 7 | 39 |
| Insufficient metaphases | 0 | 1 | 3 |
| 5q− | 5 | 1 | 11 |
| −5 | 2 | 0 | 4 |
| −5, −7 | 4 | 0 | 9 |
| −7, 7q− | 7 | 6 | 6 |
| −5, −7, +8 | 3 | 0 | 1 |
| +8 | 7 | 5 | 10 |
| 11q23 | 3 | 1 | 0 |
| Miscellaneous | 28 | 8 | 13 |
| t(6:9) | 1 | 0 | 0 |
| +21 | 0 | 4 | 3 |
| Not done | 3 | 3 | 0 |
| AHD > 2 months, % | 38 | 5 | NA |
| Treatment outcomes | |||
| Not treated | 118 | 27 | 43 |
| Remission, % | 58 | 11 | 47 |
| Relapse, % | 50 | 66 | 70 |
| Alive, % | 35 | 7 | 17 |
| Category . | AML . | MDS . | |
|---|---|---|---|
| New . | Relapsed . | ||
| No. of cases | 125 | 37 | 100 |
| Sex, female/male | 65/60 | 14/23 | 26/74 |
| Median age (range), y | 62.18 (21-86) | 55.48 (19-73) | 64.45 (21-83) |
| Race | |||
| American Indian | 0 | 1 | 0 |
| Asian | 1 | 1 | 2 |
| Black | 5 | 0 | 2 |
| Hispanic | 9 | 5 | 6 |
| White | 110 | 30 | 90 |
| FAB | |||
| Unknown | 2 | 8 | 2 (unknown) |
| M0 | 7 | 1 | 11 (CMML) |
| M1 | 12 | 6 | 17 (RA) |
| M2 | 50 | 10 | 10 (RARS) |
| M4 | 25 | 9 | 44 (RAEB) |
| M4Eos | 6 | 0 | 16 (RAEBT) |
| M5 | 12 | 2 | |
| M6 | 5 | 1 | |
| M7 | 4 | 0 | |
| Status | |||
| New | 125 | 0 | 83 |
| Post biologic | 0 | 0 | 12 |
| Relapsed | 0 | 36 | 2 |
| Relapsed resistant | 0 | 1 | 3 |
| Cytogenetics | |||
| t(8:21) | 1 | 1 | 0 |
| Inversion16 | 6 | 0 | 1 |
| Diploid | 55 | 7 | 39 |
| Insufficient metaphases | 0 | 1 | 3 |
| 5q− | 5 | 1 | 11 |
| −5 | 2 | 0 | 4 |
| −5, −7 | 4 | 0 | 9 |
| −7, 7q− | 7 | 6 | 6 |
| −5, −7, +8 | 3 | 0 | 1 |
| +8 | 7 | 5 | 10 |
| 11q23 | 3 | 1 | 0 |
| Miscellaneous | 28 | 8 | 13 |
| t(6:9) | 1 | 0 | 0 |
| +21 | 0 | 4 | 3 |
| Not done | 3 | 3 | 0 |
| AHD > 2 months, % | 38 | 5 | NA |
| Treatment outcomes | |||
| Not treated | 118 | 27 | 43 |
| Remission, % | 58 | 11 | 47 |
| Relapse, % | 50 | 66 | 70 |
| Alive, % | 35 | 7 | 17 |
Outcomes data are only for patients treated at MDACC.
FAB indicates French-American-British classification system; CMML, chronic myelomonocytic leukemia; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEBT, refractory anemia with excess blasts in transformation; AHD, antecedent hematologic disorder ≥ 2 months; and NA, not applicable.